JP2000026290A - Maintenance of muscular strength with branched chain amino acid - Google Patents

Maintenance of muscular strength with branched chain amino acid

Info

Publication number
JP2000026290A
JP2000026290A JP10226472A JP22647298A JP2000026290A JP 2000026290 A JP2000026290 A JP 2000026290A JP 10226472 A JP10226472 A JP 10226472A JP 22647298 A JP22647298 A JP 22647298A JP 2000026290 A JP2000026290 A JP 2000026290A
Authority
JP
Japan
Prior art keywords
amino acids
chain amino
muscle
branched chain
muscles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP10226472A
Other languages
Japanese (ja)
Inventor
Kaneyoshi Kubota
金嘉 窪田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CRESCENDO Corp KK
Original Assignee
CRESCENDO Corp KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CRESCENDO Corp KK filed Critical CRESCENDO Corp KK
Priority to JP10226472A priority Critical patent/JP2000026290A/en
Publication of JP2000026290A publication Critical patent/JP2000026290A/en
Pending legal-status Critical Current

Links

Abstract

PROBLEM TO BE SOLVED: To maintain the starting and persistent muscular strength at the time of motion by orally ingesting branched chain amino acids. SOLUTION: Branched chain amino acids containing (A) leucine, (B) isoleucine and (C) valine as active ingredients are included so as to preferably provide 1:2:1 formulation ratio of the ingredients A:B:C and orally ingested. When the branched chain amino acids are orally ingested, the daily dose thereof for an adult is about 500-2,000 mg expressed in terms of the active ingredients and ingested in divided one to several portions to thereby provide desired effects without adverse effects. The breakdown of muscles is suppressed by ingesting a branched chain amino acid formulated preparation before motion to improve the deterioration in muscular strength, muscular fatigue, central fatigue, etc. The branched chain amino acids are directly degraded and oxidized in peripheral muscular tissues to provide an energy source. Since the muscular metabolism is promoted and hydrolysis of myoproteins is suppressed, the consumption of muscles can be prevented to restore the muscles in a short time.

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【発明の属する技術分野】激しい運動をすると、筋肉に
大きなダメージを受け、筋肉疲労や筋力低下をきたしま
す。このダメージが筋肉痛や筋肉のハリをひきおこし、
運動能力の低下につながります。この状態を続けている
と怪我につながり、肉離れ、ぎっくり腰、頸・肩・腕症
候群、こむら返し等になりやすく、スポーツを続けるこ
とが困難になります。激しい運動をする選手は、運動能
力向上と怪我の予防のために骨格筋を強化しますが、簡
単に食事だけで増大させることは難しく、一般的には体
づくりのため、大量の蛋白質を摂取することが推奨され
ています。しかし、アスリートの蛋白質の要求量は一般
人より多いのですが、アンモニア態窒素を処理するため
に腎臓などに負担がかかることから、大量の蛋白質を摂
取することは避けることが望ましいのです。運動中筋タ
ンパク質を分解し、生じたロイシンなどをアラニンに変
換して血液中に放出し、肝臓で糖新生の基質にする経路
が存在する(グルコース−アラニンサイクル)。運動が
長時間にわたると、この経路で分解される筋タンパク質
の量が無視できないレベルになり、せっかく作り上げた
筋タンパク質が壊されてしまう事態に陥ります。筋肉タ
ンパク質を増大させることは簡単ではないにもかかわら
ず、運動を遂行するため骨格筋の分解が簡単に起こりま
す。分解が起きた筋肉では、必要に応じて筋タンパク質
の再合成が行われますが、同じ筋肉をスクラップ・アン
ド・ビルドしていてはエネルギーの無駄遣いであり、高
いレベルで競技を行っているアスリートにとっては、筋
力が維持できない事態になります。このような事態を避
けるために、運動を開始する前に分岐鎖アミノ酸(BC
AA)を摂取して、血中のこれらのアミノ酸濃度を高め
ておくと筋タンパク質の分解が有意に抑制されます。本
発明は筋タンパク質の分解を防ぐ手段として、分岐鎖ア
ミノ酸(BCAA)を経口摂取することにより、筋力低
下、筋肉疲労、中枢性疲労を起こりにくくするものであ
ります。
[Technical field to which the invention pertains] Exercise can cause severe damage to muscles, causing muscle fatigue and weakness. This damage causes muscle pain and muscle tension,
It leads to a decrease in athletic ability. If you keep this condition, you will be injured, you will be liable to lose your muscles, your hips, neck / shoulder / arm syndrome, and swelling will be difficult to continue sports. Intense athletes strengthen skeletal muscles to improve athletic performance and prevent injuries, but it is difficult to increase them simply by eating and generally consumes a large amount of protein for body building It is recommended that you However, although athletes require more protein than ordinary people, it is desirable to avoid ingesting a large amount of protein because the processing of ammonia nitrogen puts a burden on the kidneys and the like. During exercise, there is a pathway that degrades muscle proteins, converts leucine and the like to alanine, releases it into the blood, and makes it a substrate for gluconeogenesis in the liver (glucose-alanine cycle). If you exercise for a long time, the amount of muscle protein that is degraded by this pathway will become a non-negligible level, and the muscle protein you have made will be destroyed. Despite the fact that increasing muscle protein is not easy, skeletal muscle breakdown occurs easily to perform exercise. Degraded muscles undergo re-synthesis of muscle proteins as needed, but scrapping and building the same muscles is a waste of energy and is an athlete who competes at a high level. Can not maintain muscle strength. To avoid this situation, before starting exercise, use branched-chain amino acids (BC
Ingesting AA) and increasing the concentration of these amino acids in the blood significantly reduces muscle protein degradation. In the present invention, as a means of preventing the breakdown of muscle proteins, oral intake of branched-chain amino acids (BCAA) reduces muscular weakness, muscle fatigue, and central fatigue.

【0002】[0002]

【従来の技術】激しいスポーツをすれば、筋肉は酷使さ
れます。筋肉は元来、ごく細い筋繊維の束でできてお
り、激しい運動を繰り返すと、この筋繊維は何百本、何
千本と切れてしまいます。切れた筋繊維は2時間程度で
つながりますが、この時、筋肉の原材料であるアミノ酸
が必要になります。特に分岐鎖アミノ酸(ロイシン、イ
ソロイシン、バリン)と呼ばれる必須アミノ酸は重要な
鍵を握っています。こうしてつながった筋繊維はその後
切れにくくなり、その繰り返しにより筋肉全体が強くな
っていきます。ところが、体内に筋肉の原材料であるア
ミノ酸が不足すると、赤血球を使うために、鉄分が不足
して貧血等の要因となり、筋肉の修復が不可能になりま
す。筋繊維の修復には、必要な原材料をいかにすみやか
に筋肉に届けられるかが重要な課題になります。現在、
運動時及び運動後の筋肉疲労には、スポーツサプリメン
トとして数多く販売されておりますが、筋肉合成の材料
としてではなくて、筋肉の合成・分解の制御に影響を与
える商品は見当りません。
2. Description of the Related Art Muscles are overworked during intense sports. Muscles are originally made up of very thin bundles of muscle fibers, and when you exercise hard, hundreds or thousands of muscle fibers can break. The broken muscle fiber is connected in about 2 hours, but at this time, amino acids that are the raw materials of muscle are needed. In particular, the essential amino acids called branched-chain amino acids (leucine, isoleucine, valine) hold an important key. The connected muscle fibers are then less likely to break, and the repetition strengthens the entire muscle. However, if the body lacks amino acids, which are the raw materials of muscles, the use of red blood cells causes a shortage of iron, causing anemia and other factors, making muscle repair impossible. An important issue in muscle fiber repair is how to deliver the necessary raw materials to muscles as quickly as possible. Current,
Many muscle supplements are sold as a sports supplement for exercise and post-exercise muscle fatigue, but there is no product that affects muscle synthesis / decomposition control, not as a material for muscle synthesis.

【0003】[0003]

【発明が解決しようとする課題】体内で合成できず、体
外からの補給が必要なアミノ酸を必須アミノ酸と呼び、
ロイシン、イソロイシン、バリン(以上分岐鎖アミノ
酸)、フェニルアラニン、トリプトファン(以上芳香族
アミノ酸)、メチオニン(含硫アミノ酸)、リジン(塩
基性アミノ酸)、トレオニン(OH基を有するアミノ
酸)の8種類があります。これに、体内合成が可能であ
るが不十分なために準必須アミノ酸であるアルギニン、
ヒスチジンを加えて10種類を、栄養学的必須アミノ酸
と称しています。これらのうち、ロイシン、イソロイシ
ン、バリンは、いずれも分岐構造を有することから分岐
鎖アミノ酸(BCAA)と総称されます。BCAAはい
ずれも必須アミノ酸であり、主として筋で代謝され、エ
ネルギーの産生、筋蛋白代謝の調整という特異な生理作
用を示すため、肝臓で代謝される他の多くのアミノ酸と
は異なります。したがって、本発明は、ロイシン、イソ
ロイシン、バリンを有効成分とする分岐鎖アミノ酸(B
CAA)を経口摂取することにより、筋肉タンバク質の
代謝回転の性質上、激しい運動時において、いったん出
来上った筋肉を分解から守ることが重要であり、アスリ
ート達の運動能力を維持し続けることが課題でありま
す。
The amino acids that cannot be synthesized in the body and need to be replenished from outside the body are called essential amino acids,
There are eight types: leucine, isoleucine, valine (above branched-chain amino acids), phenylalanine, tryptophan (above aromatic amino acids), methionine (sulfur-containing amino acids), lysine (basic amino acids), and threonine (amino acids having an OH group). In addition, arginine, a semi-essential amino acid that can be synthesized in the body but is insufficient,
Histidine plus 10 types are called nutritionally essential amino acids. Of these, leucine, isoleucine, and valine all have a branched structure and are therefore collectively referred to as branched-chain amino acids (BCAA). BCAAs are all essential amino acids and are metabolized mainly in muscles. They exhibit unique physiological effects such as energy production and regulation of muscle protein metabolism, so they are different from many other amino acids metabolized in the liver. Therefore, the present invention provides a branched-chain amino acid (B) containing leucine, isoleucine and valine as active ingredients.
Due to the nature of muscle protein turnover by ingesting CAA), it is important to protect the muscle once it is completed during intense exercise and to maintain the athletic ability of athletes Is the challenge.

【0004】[0004]

【課題を解決するための手段】本発明は、ロイシン、イ
ソロイシン、バリンを有効成分とする分岐鎖アミノ酸
が、必須アミノ酸の約40%を占め、摂取された他のア
ミノ酸の大部分が肝臓で蛋白合成や糖新生に利用される
のに対して、筋肉を主として、腎などの肝以外の組織で
利用される臓器特異性を有することに着目して、運動時
の筋力維持に役立てることを見いだした。さらに詳しく
は、骨格筋は最大のアミノ酸プールであり、骨格筋には
大量のBCAAが含まれている。骨格筋のBCAAのア
ミノ基を用いてアラニンが生成され、肝臓での糖新生な
どに供給される。また、骨格筋はBCAAの主要な代謝
の場であり、骨格筋蛋白の異化亢進によりBCAAの代
謝が亢進する。したがって、BCAAのアミノ基転移に
よって生じたアミノ基は、糖代謝の過程でグルコースか
ら生じたピルビン酸と結合し、糖原性アミノ酸であるア
ラニンとなって肝臓に運ばれ、糖新生に利用される。こ
れはglucose alanine cycle と
呼ばれ、骨格筋と肝臓での物質交換による糖新生系とし
て重要な役割を果たしており(muscle live
r fuel cycle)、また、尿素合成の機構を
持たない筋組織から、アンモニアを肝臓へ運び解毒する
作用も担っている。この筋蛋白の崩壊は、尿中の窒素排
泄量の増加と、尿中3−メチルヒスチジン排泄量によっ
てとらえることができる。一方、BCAAの脱アミノ化
された炭素骨格も、ピルビン酸、アセチルCoA、アセ
ト酢酸というTCA(tricarboxylic a
cid)cycleまたは糖新生系を構成する物質に替
わって糖新生に用いられる。体蛋白分解の亢進が糖新生
を目的とするものであることは、ブドウ糖投与によって
それが抑制されることで証明されており、protei
n sparing effectofglucose
と呼ばれる。アミノ基転移酵素が肝臓にはほとんどない
ことから、肝臓では代謝を受けず、主に末梢の筋肉組織
で異化反応を受ける。つまり、肝機能の状態にかかわら
ず、BCAAは末梢で消費され、血中濃度は低下し、末
梢への取り込みを促進させる。BCAAの経口摂取によ
り、筋蛋白の分解が抑制されることが示されている。特
にロイシンが筋蛋白の生合成を促進し、逆に蛋白分解を
抑制する調整役を担っている。蛋白節約作用の他にも、
グルタミン、アラニンの放出、膵臓からのインスリンの
放出、各組織におれるアミノ酸の取り込み、さらには、
脂肪組織におけるコレステロール、中性脂肪の代謝にも
関与し、効率的蛋白代謝を行うには、ロイシンと他の分
岐鎖アミノ酸(イソロイシン、バリン)の配合比が重要
であります。脳への中性アミノ酸の輸送において、BC
AAやAAA(芳香族アミノ酸)は中性アミノ酸であ
り、これらは共通のcarrierと結合して血液脳関
門を通過するが、中性アミノ酸の脳内への取り込みはc
ompetitiveであり、BCAAの相対的濃度が
低いとAAAの取り込み量が増加します。AAAは本来
の神経伝達アミンであるドバミン、ノルエピネフリン、
セロトニンの前駆物質であるが、この脳内neurot
ransmitter(神経伝達物質)の減少ととも
に、増加した脳内のフェニルアラニンやチロシンから生
成された脳内アミン(オクトパミン、チラミン、フェニ
ルエタノラミン、フェネチラミン)が増加する。これら
は偽神経伝達物質(falseneurotransm
itter)として、本来の神経伝達アミンであるドパ
ミン、ノルエピネフリンを阻害する。こうしたBCAA
やAAAのインバランスが脳内アミンの異常をもたら
す。激しい運動を行っている時は、BCAAやAAAの
インバランスが脳内アミンの異常を起こすため、運動後
の筋タンパク質合成が上昇する時期に、充分な分岐鎖ア
ミノ酸(BCAA)を経口摂取することが筋肉づくりに
は重要であります。
According to the present invention, a branched-chain amino acid containing leucine, isoleucine and valine as active ingredients accounts for about 40% of essential amino acids, and most of the other amino acids ingested are protein in the liver. Focusing on the fact that it is used for synthesis and gluconeogenesis, it has an organ specificity used mainly for muscles and other tissues other than the liver, such as the kidneys, and has been found to be useful for maintaining muscle strength during exercise. . More specifically, skeletal muscle is the largest pool of amino acids, and skeletal muscle contains large amounts of BCAAs. Alanine is produced using the amino group of BCAA of skeletal muscle and is supplied to gluconeogenesis in the liver. In addition, skeletal muscle is a major metabolic site of BCAA, and the metabolism of BCAA is enhanced by enhanced catabolism of skeletal muscle protein. Therefore, the amino group generated by transamination of BCAA binds to pyruvate generated from glucose in the course of glucose metabolism, becomes alanine, a glycogenic amino acid, is transported to the liver, and is used for gluconeogenesis. . This is called a glucose alanine cycle and plays an important role as a gluconeogenesis system by mass exchange between skeletal muscle and liver (muscle live).
r fuel cycle), and also carries the action of carrying ammonia to the liver from muscle tissues without a mechanism of urea synthesis to the liver and detoxifying it. This breakdown of muscle protein can be detected by an increase in the amount of excreted nitrogen in urine and an amount of excreted 3-methylhistidine in urine. On the other hand, the deaminated carbon skeleton of BCAA is also composed of pyruvate, acetyl-CoA, and acetoacetate (TCA).
cid) It is used for gluconeogenesis instead of cycle or a substance constituting the gluconeogenesis system. The fact that the enhancement of body protein degradation is aimed at gluconeogenesis has been proved by the fact that glucose administration suppresses it.
n sparing effectglucose
Called. Since there is almost no transaminase in the liver, it is not metabolized in the liver and undergoes catabolism mainly in peripheral muscle tissue. That is, regardless of the state of liver function, BCAA is consumed in the periphery, the blood concentration decreases, and the uptake into the periphery is promoted. It has been shown that oral intake of BCAA suppresses muscle protein degradation. In particular, leucine promotes muscle protein biosynthesis and, conversely, plays a role in regulating protein degradation. In addition to the protein-saving effect,
Release of glutamine and alanine, release of insulin from pancreas, uptake of amino acids in each tissue, and
It is involved in the metabolism of cholesterol and triglyceride in adipose tissue, and the ratio of leucine to other branched-chain amino acids (isoleucine, valine) is important for efficient protein metabolism. In the transport of neutral amino acids to the brain, BC
AA and AAA (aromatic amino acids) are neutral amino acids, which bind to common carriers and pass through the blood-brain barrier, but the uptake of neutral amino acids into the brain is c
Ompetitive, low levels of BCAA increase AAA uptake. AAA is the original neurotransmitter amine dobamine, norepinephrine,
A precursor of serotonin, this neurot in the brain
Along with a decrease in transmitter (neurotransmitter), an increase in cerebral amines (octopamine, tyramine, phenylethanolamine, phenethylamine) generated from phenylalanine and tyrosine in the brain increases. These are false neurotransmitters
Itter) inhibits the original neurotransmitter amines dopamine and norepinephrine. Such BCAA
And AAA imbalance cause brain amine abnormalities. When exercising vigorously, sufficient intake of branched-chain amino acids (BCAA) should be taken orally when muscle protein synthesis increases after exercise because BCAA and AAA imbalance causes abnormalities in brain amines. But it is important for building muscle.

【0005】[0005]

【発明の実施の形態】本発明の瞬発的・持久的筋力維持
剤は、ロイシン・イソロイシン・バリンを有効成分とす
る分岐鎖アミノ酸を、自体公知の食品あるいは食品成
分、医薬担体または賦形剤と自体公知の方法で合して、
筋肉の瞬発力・持久力を維持する食品とすることができ
ます。用いる食品あるいは食品成分は特に限定するもの
ではなく、目的とする筋力維持剤の具体的用途に応じて
当業者が適宜選択できます。また、筋力維持剤の形態も
特に限定するものではなく、具体的用途に応じて、種々
の個体や形状にすることができます。本発明の瞬発的・
持久的筋力維持剤の効果を発揮させるために、特に重要
なことは分岐鎖アミノ酸の配合比を、イソロイシン:ロ
イシン:バリンの比率が1:2:1に近い配合がもっと
も有意であり、この配合比を考慮して製品化することが
大切であります。体内摂取の方法は経口摂取であり、ロ
イシン・イソロイシン・バリンを有効成分とする分岐鎖
アミノ酸を経口摂取の場合、成人に対して1日あたり、
有効成分として500mg〜2,000mg程度とし
て、これを1日1〜数回に分けて摂取することにより、
副作用なく所望の効果を発揮させることができます。
BEST MODE FOR CARRYING OUT THE INVENTION The instantaneous / endurable muscular strength maintenance agent of the present invention comprises a branched chain amino acid containing leucine / isoleucine / valine as an active ingredient, which is combined with a known food or food ingredient, a pharmaceutical carrier or an excipient. Combined by a method known per se,
It can be used as a food that maintains muscle power and endurance. The food or food ingredient to be used is not particularly limited, and can be appropriately selected by those skilled in the art according to the specific use of the intended muscle strength maintaining agent. Also, the form of the muscle strength maintaining agent is not particularly limited, and can be made into various individuals and shapes depending on the specific use. The instantaneous
In order to exert the effect of the endurance muscular strength maintenance agent, it is particularly important that the mixing ratio of the branched-chain amino acids is most significant when the ratio of isoleucine: leucine: valine is close to 1: 2: 1. It is important to commercialize in consideration of the ratio. The method of ingestion is oral ingestion, and in the case of oral ingestion of a branched-chain amino acid containing leucine, isoleucine, and valine as an active ingredient, for adults,
By taking about 500 mg to 2,000 mg as an active ingredient and ingesting it once or several times a day,
We can show desired effect without side effect.

【0006】[0006]

【実施例】本発明の瞬発的・持久的筋力維持剤を、5粒
中で分岐鎖アミノ酸を630mg配合して製品化した。
形状は打錠品のタブレットとした。他の食品成分とし
て、アルギニン、グルタミン酸、アスパラギン酸Na、
乳糖、コラーゲンを配合した。このようにして製品化さ
れた筋力維持剤を、22才のデ杯選手のテニスプレヤー
に経口摂取することを依頼して、試合1時間前に10粒
程度を摂取、試合後すぐに10粒程度を摂取した。試合
中の筋肉疲労もまったく感じられず、充分に自分の能力
を発揮することができた。翌日の試合に対しても筋肉痛
や筋肉のはりもなく、筋力低下や筋肉疲労もみられなか
った。また、中枢性疲労においても試合中感じられなか
った。試合の結果は、欧州サーキットで単・複3回優
勝。マスターズで準優勝とすばらしい成績を収めた。
EXAMPLES The instantaneous / endurable muscular strength maintaining agent of the present invention was commercialized by blending 630 mg of a branched-chain amino acid in 5 tablets.
The shape was a tablet tablet. As other food ingredients, arginine, glutamic acid, sodium aspartate,
Lactose and collagen were blended. We asked the 22-year-old tennis player, a cup player, to orally ingest the muscular strength agent commercialized in this way, and ingested about 10 tablets one hour before the game and about 10 tablets immediately after the game. Ingested. I couldn't feel any muscle fatigue during the game, so I was able to fully demonstrate my ability. There was no muscle pain or muscle sting, no weakness or no muscle fatigue in the next day's game. No central fatigue was felt during the game. The result of the match was a single and double win at the European Circuit. He finished second in the Masters and achieved excellent results.

【0007】[0007]

【発明の効果】スポーツ選手が、激しい運動を行うと、
筋肉の組織が分解されてしまいます。運動前に分岐鎖ア
ミノ酸配合の筋力維持剤を摂取することにより、筋肉の
分解が抑えられ、筋力低下、筋肉疲労、中枢性疲労とい
つた悩みを解決します。運動の翌日も筋肉はベストコン
ディションを維持できます。分岐鎖アミノ酸(ロイシ
ン、イソロイシン、バリン)は運動中のエネルギーとし
て利用されるアミノ酸です。これを運動前に補給するこ
とで糖質の消費を節約でき、運動能力維持に役立ちま
す。運動中の筋肉疲労は、筋肉で生成される乳酸という
物質が原因です。この乳酸の生成をおさえるのがロイシ
ン、イソロイシン、バリンの3種類の必須アミノ酸で
す。長時間の運動時にも筋肉疲労、筋力低下が起こりに
くくなり、瞬発力及び持久力への運動能力が維持されま
す。また、中枢性疲労においても、BCAAを経口摂取
することにより、BCAAの血液濃度が増加し、血液脳
関門における中性アミノ酸の競合と脳内モノアミンの変
動を是正するため、運動時の中枢性疲労を感じさせませ
ん。分岐鎖アミノ酸(BCAA)は、末梢筋組織で直接
分解・酸化されてエネルギー源となり、筋肉代謝の促進
と筋蛋白の分解を抑制しますから、、筋肉の消耗を防
ぎ、短時間で筋肉の修復が可能になり、運動能力が維持
されます。
According to the present invention, when an athlete performs intense exercise,
Muscle tissue is broken down. Ingesting a muscle-strengthening agent containing branched-chain amino acids before exercise reduces muscle breakdown and resolves problems such as muscle weakness, muscle fatigue, and central fatigue. Muscles can be maintained in the best condition the day after exercise. Branched chain amino acids (leucine, isoleucine, valine) are amino acids used as energy during exercise. Replenishing it before exercise can save carbohydrate consumption and help maintain exercise performance. Muscle fatigue during exercise is caused by a substance called lactic acid, which is produced in the muscles. The three essential amino acids, leucine, isoleucine, and valine, suppress this lactic acid production. Even during prolonged exercise, muscle fatigue and muscle weakness are less likely to occur, and exercise ability for instantaneous power and endurance is maintained. In addition, in the case of central fatigue, oral intake of BCAA increases the blood concentration of BCAA and corrects competition of neutral amino acids at the blood-brain barrier and changes in monoamines in the brain. I do not feel. Branched chain amino acids (BCAAs) are directly decomposed and oxidized in peripheral muscle tissue to become an energy source, which promotes muscle metabolism and suppresses the breakdown of muscle proteins, thus preventing muscle wasting and repairing muscles in a short time. Is possible, and athletic ability is maintained.

Claims (1)

【特許請求の範囲】[Claims] 【請求項1】分岐鎖アミノ酸を経口摂取することによる
運動時の瞬発的・持久的筋力維持。
(1) An instantaneous and endurable maintenance of muscle strength during exercise by ingesting a branched-chain amino acid orally.
JP10226472A 1998-07-07 1998-07-07 Maintenance of muscular strength with branched chain amino acid Pending JP2000026290A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP10226472A JP2000026290A (en) 1998-07-07 1998-07-07 Maintenance of muscular strength with branched chain amino acid

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP10226472A JP2000026290A (en) 1998-07-07 1998-07-07 Maintenance of muscular strength with branched chain amino acid

Publications (1)

Publication Number Publication Date
JP2000026290A true JP2000026290A (en) 2000-01-25

Family

ID=16845644

Family Applications (1)

Application Number Title Priority Date Filing Date
JP10226472A Pending JP2000026290A (en) 1998-07-07 1998-07-07 Maintenance of muscular strength with branched chain amino acid

Country Status (1)

Country Link
JP (1) JP2000026290A (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002034257A1 (en) * 2000-10-27 2002-05-02 Meiji Dairies Corporation Agents for recoverying from or preventing fatigue in the central nerve system and foods for recoverying from or preventing fatigue
US6855727B2 (en) 2000-12-04 2005-02-15 Yaizu Suisankagaku Industry Co., Ltd. Muscular fatigue-controlling composition and method for providing muscular fatigue-controlling effect
WO2006070874A1 (en) * 2004-12-28 2006-07-06 Toudai Tlo, Ltd. Hypoxic response promoter
WO2007029730A1 (en) * 2005-09-06 2007-03-15 Meiji Dairies Corporation Amino acid composition for prevention or treatment of senile anemia
WO2008004340A1 (en) 2006-07-05 2008-01-10 Kao Corporation Senescence inhibitor
WO2008044691A1 (en) 2006-10-10 2008-04-17 Otsuka Pharmaceutical Factory, Inc. Antidepressant agent
EP2108367A1 (en) * 2006-12-12 2009-10-14 Ajinomoto Co., Inc. Composition for amelioration/prevention of adverse side effect in steroid therapy
WO2013021891A1 (en) * 2011-08-08 2013-02-14 味の素株式会社 Amino-acid-containing composition for enhancing recovery from muscle fatigue
WO2018043694A1 (en) * 2016-09-02 2018-03-08 味の素株式会社 Composition for improving muscular endurance
WO2020260689A1 (en) * 2019-06-28 2020-12-30 Dompe' Farmaceutici Spa New composition containing branched-chain amino acids
JP2021004211A (en) * 2019-06-26 2021-01-14 株式会社東洋新薬 Amino acid absorption promoting composition
CN114786502A (en) * 2020-04-03 2022-07-22 三菱瓦斯化学株式会社 Muscle-building agent

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002034257A1 (en) * 2000-10-27 2002-05-02 Meiji Dairies Corporation Agents for recoverying from or preventing fatigue in the central nerve system and foods for recoverying from or preventing fatigue
US6855727B2 (en) 2000-12-04 2005-02-15 Yaizu Suisankagaku Industry Co., Ltd. Muscular fatigue-controlling composition and method for providing muscular fatigue-controlling effect
WO2006070874A1 (en) * 2004-12-28 2006-07-06 Toudai Tlo, Ltd. Hypoxic response promoter
JP5220415B2 (en) * 2005-09-06 2013-06-26 株式会社明治 Amino acid composition for preventing or treating senile anemia
WO2007029730A1 (en) * 2005-09-06 2007-03-15 Meiji Dairies Corporation Amino acid composition for prevention or treatment of senile anemia
WO2008004340A1 (en) 2006-07-05 2008-01-10 Kao Corporation Senescence inhibitor
US8962678B2 (en) 2006-07-05 2015-02-24 Kao Corporation Senescence inhibitor
WO2008044691A1 (en) 2006-10-10 2008-04-17 Otsuka Pharmaceutical Factory, Inc. Antidepressant agent
US9060979B2 (en) 2006-10-10 2015-06-23 Otsuka Pharmaceutical Factory, Inc. Antidepressant
EP2606882A1 (en) * 2006-12-12 2013-06-26 Ajinomoto Co., Inc. Composition for amelioration/prevention of adverse side effect in steroid therapy
EP2108367A4 (en) * 2006-12-12 2010-03-03 Ajinomoto Kk Composition for amelioration/prevention of adverse side effect in steroid therapy
EP2108367A1 (en) * 2006-12-12 2009-10-14 Ajinomoto Co., Inc. Composition for amelioration/prevention of adverse side effect in steroid therapy
WO2013021891A1 (en) * 2011-08-08 2013-02-14 味の素株式会社 Amino-acid-containing composition for enhancing recovery from muscle fatigue
JPWO2013021891A1 (en) * 2011-08-08 2015-03-05 味の素株式会社 Amino acid-containing composition for promoting recovery from muscle fatigue
US11077081B2 (en) 2011-08-08 2021-08-03 Ajinomoto Co., Inc. Amino-acid-containing composition for enhancing recovery from muscle fatigue
WO2018043694A1 (en) * 2016-09-02 2018-03-08 味の素株式会社 Composition for improving muscular endurance
JPWO2018043694A1 (en) * 2016-09-02 2019-06-24 味の素株式会社 Composition for improving muscle endurance
JP2021004211A (en) * 2019-06-26 2021-01-14 株式会社東洋新薬 Amino acid absorption promoting composition
JP7385243B2 (en) 2019-06-26 2023-11-22 株式会社東洋新薬 Composition for promoting amino acid absorption
WO2020260689A1 (en) * 2019-06-28 2020-12-30 Dompe' Farmaceutici Spa New composition containing branched-chain amino acids
CN114786502A (en) * 2020-04-03 2022-07-22 三菱瓦斯化学株式会社 Muscle-building agent

Similar Documents

Publication Publication Date Title
US5026721A (en) Amino acid nutritional supplement and regimen for enhancing physical performance through sound nutrition
US5817329A (en) Nutritional supplement for increased muscle size and strength for body builders
Mero Leucine supplementation and intensive training
Clarkson Nutrition for improved sports performance: current issues on ergogenic aids
US6159942A (en) Compositions for increasing energy in vivo
Stevens et al. High-intensity dynamic human muscle performance enhanced by a metabolic intervention
Benzi Is there a rationale for the use of creatine either as nutritional supplementation or drug administration in humans participating in a sport?
JP2001517085A (en) Nutrition supplements to facilitate the application of skeletal muscle to intense exercise and to address fatigue in asthenia
US6534480B2 (en) Compositions for increasing energy in vivo
JP2000026290A (en) Maintenance of muscular strength with branched chain amino acid
EP2875736A1 (en) N-Carbamoylputrescine to enhance muscle protein synthesis
EP0449787A2 (en) Pharmaceutical, dietetic or veterinary compositions with eumetabolic activity
WO2003011056A1 (en) Ergogenic food compositions
JP2000026289A (en) Effect of branched chain amino acid on myalgia, stiffness and tensity of muscle
US6294579B1 (en) Method for improving delivery of tyrosine supplementation
CA2595212A1 (en) Nutrient supplement and use of the same
US20080161380A1 (en) Amino acid composition
US9533946B1 (en) N-carbamoylputrescine to enhance muscle protein synthesis
EP2042170B1 (en) Creatine composition and use
US20050090545A1 (en) Nitric oxide topical technology
JP2000128784A (en) Hangover symptom
Cooke et al. Effective nutritional supplement combinations
Wilborn et al. Ergogenic aids
CA2488463C (en) Creatine composition and use
Meckes et al. The effects of carbohydrate-electrolyte drinks on physical and mental performance